Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

completed267%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Next Generation Rocklatan

NCT06441643
enrolling_by_invitation

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

NCT06969586
completedearly_phase_1

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

NCT04057053

Clinical Trials (3)

Showing 3 of 3 trials
NCT06441643Phase 2

Next Generation Rocklatan

Completed
NCT06969586

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Enrolling By Invitation
NCT04057053Early Phase 1

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3